The company's device includes a percutaneous catheter for treating acute ischemic stroke, a rapid aspiration thrombectomy system, and intra-cerebral implant delivery. Route 92 Medical aims to improve outcomes for patients undergoing minimally invasive brain procedures. They focus on developing next-generation products in collaboration with leading clinicians to treat challenging diseases such as stroke. The Monopoint operating platform received U.S. FDA 510(k) clearance in 2020, and the company is currently enrolling the SUMMIT MAX randomized controlled trial under an FDA-approved Investigational Device Exemption.